KR900701843A - 사람 Fcr 수용체 III - Google Patents

사람 Fcr 수용체 III

Info

Publication number
KR900701843A
KR900701843A KR1019900700147A KR900700147A KR900701843A KR 900701843 A KR900701843 A KR 900701843A KR 1019900700147 A KR1019900700147 A KR 1019900700147A KR 900700147 A KR900700147 A KR 900700147A KR 900701843 A KR900701843 A KR 900701843A
Authority
KR
South Korea
Prior art keywords
stands
ala
ser
asn
asp
Prior art date
Application number
KR1019900700147A
Other languages
English (en)
Other versions
KR0149012B1 (ko
Inventor
에이. 펠쯔 개리
더블유. 무어 케빈
Original Assignee
죤 티. 포가티
쉐링 바이오테크 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 죤 티. 포가티, 쉐링 바이오테크 코포레이션 filed Critical 죤 티. 포가티
Publication of KR900701843A publication Critical patent/KR900701843A/ko
Application granted granted Critical
Publication of KR0149012B1 publication Critical patent/KR0149012B1/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)

Abstract

내용 없음

Description

사람 Fcr 수용체 Ⅲ
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 가용성이거나 막-결합된 사람 FcrRⅢ로 이루어진 단백질.
  2. 제1항에 있어서, 사람 FcrRⅢ의 세포의 영역으로 이루어진 단백질.
  3. 제1항에 있어서 2회 치환되고 1회 결실된 하기서열식으로 이루어진 그룹중에서 선택된 아미노산 서열을 갖는 단백질.
    또는
    상기 서열식에서, X(Ala)는 Ala, Ser, Thr 또는 Gly를 나타내고, X(Arg)는 Arg 또는 Lys를 나타내며, X(Asn)는 Asn,Asp 또는 Ser를 나타내며, X(Asp)는 Asp,Glu 또는 Asn를 나타내며, X(Cys)는 Cys이며, X(Gln)는 Gln 또는 Glu를 나타내며, X(Glu) 는 Glu,Asp 또는 Gln를 나타내며, X(Gly)는 Gly,Ala 또는 Ser를 나타내며, X(His)는 His 또는 Asn를 나타내며, X(Ile)는 Ile,Val 또는 Leu를 나타내며, X(Leu)는 Leu, Val 또는 Ile를 나타내며, X(Lys)는 Lys,Arg 또는 Asn를 나타내며, X(Met)는 Met 또는 Leu를 나타내며, X(Phe)는 Phe이며, X(Pro)는 Pro 또는 Ala를 나타내며, X(Ser)는 Ser,Ala,Thr,Gly 또는 Asn를 나타내며, X(Thr)는 Thr, Ser, Ala 또는 Lys를 나타내며, X(Trp)는 Trp이며, X(Tyr)는 Tyr이며, X(Val)는 Val, Ile, Ala 또는 Leu이다
  4. 제3항에 있어서, 언급된 그룹이 언급된 서열식의 1회 치환된 서열로 이루어진 단백질.
  5. 제3항에 있어서, X(Ala)는 Ala 또는 Ser를 나타내고, X(Arg)는 Arg이며, X(Asn)는 Asn 또는 Asp를 나타내며, X(Asp)는 Asp 또는 Glu를 나타내며, X(Cys)는 Cys이며, X(Gln)는 Gln이며, X(Glu)는 Glu 또는 Asp를 나타내며, X(Gly)는 Gly 또는 Ala를 나타내며, X (His)는 His이며, X(Ile)는 Ile 또는 Val를 나타내며, X(Leu)는 Leu 또는 Va1를 나타내며, X(Lys)는 Lys 또는 Arg를 나타내며 X(Met)는 Met이며, X(Phe)는 Phe이며, X(Pro)는 Pro이며, X(Ser)는 Ser,Ala 또는 Thr를 나타내며, X(Thr)는 Thr,Ser 또는 Ala를 나타내며, X(Trp)는 Trp이며, X(Tyr)는 Tyr이며, X(Val)는 Val 또는 Ile인 단백질.
  6. 제5항에 있어서, 언급된 그룹이 언급된 서열식의 1회 치환된 서열로 이루어진 단백질.
  7. 제6항에 있어서, 하기 아미노산 서열을 갖는 단백질.
    또는
  8. 가용성이거나 막-결합된 사람 FcrRⅢ를 암호화할 수 있는 핵산.
  9. 제8항에 있어서, 2회 치환되고 1회 결실된 하기 서열식 중에서 선택된 아미노산 서열을 갖는 폴리펩타이드를 암호화할 수 있는 핵산.
    또는
    상기 서열식에서, X(Xaa)로 나타낸 각종 아미노산들은 제3항에서 정의한 바와 같다.
  10. 제9항에 있어서, 하기 아미노사 서열중에서 선택된 폴리펩타이드를 암호화할 수 있는 핵산.
    또는
  11. 유효량의 가용성 사람 FcrRⅢ를 투여함을 특징으로 하여 사람의 면역 혈소판 감소성 자반병을 치료하는 방법.
  12. 제11항에 있어서, 투여단계가 약 1 내지 2O㎎/사람 체중 ㎏/1일의 범위의 양으로 가용성 사람 FcrRⅢ를 정맥내 수송함을 포함하는 방법.
  13. 세포의 표면에서 발현되는 FcrRⅢ를 암호화하는 cDNA삽입물을 함유하는 벡터로 형질전환시킨 세포를 제공하고, 면역복합체가 FcrRⅢ에 의해 세포의 표면에 부착할수 있도록 세포를 면역복합체 함유샘플에 노출시키고, 세포 표면에 부착되는 면역복합체를 표지하며, 세포에 부착되는 표지된 면역복합체의 양을 측정하는 단계를 포함함을 특징으로 하는, 샘플내의 면역복합체의 검출방법.
  14. 제13항에 있어서, 세포가 마우스 1 세로 또는 C0S원숭이 세포이고, 벡터가 pcD(SPα)-GP 5 및 pcD(SPα)-NL 10중에서 선택되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700147A 1988-05-27 1989-05-24 사람 f크롬 수용체 iii KR0149012B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19951388A 1988-05-27 1988-05-27
US199513 1988-05-27
US30003989A 1989-01-19 1989-01-19
US300039 1989-01-19
PCT/US1989/002182 WO1989011490A1 (en) 1988-05-27 1989-05-24 HUMAN Fcgamma RECEPTOR III

Publications (2)

Publication Number Publication Date
KR900701843A true KR900701843A (ko) 1990-12-04
KR0149012B1 KR0149012B1 (ko) 1998-08-17

Family

ID=26894851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700147A KR0149012B1 (ko) 1988-05-27 1989-05-24 사람 f크롬 수용체 iii

Country Status (11)

Country Link
US (2) US5976831A (ko)
EP (3) EP0449828A1 (ko)
JP (1) JP2657221B2 (ko)
KR (1) KR0149012B1 (ko)
AT (2) ATE197053T1 (ko)
AU (1) AU3740089A (ko)
DE (3) DE68929256T2 (ko)
ES (2) ES2150898T3 (ko)
GR (1) GR3034698T3 (ko)
HK (1) HK1001403A1 (ko)
WO (1) WO1989011490A1 (ko)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657221B2 (ja) * 1988-05-27 1997-09-24 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ ヒトＦｃγレセプター▲ＩＩＩ▼
US5767077A (en) * 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
US7038031B1 (en) * 1989-07-28 2006-05-02 Sloan-Kettering Institute For Cancer Research DNA encoding FcγR receptor protein on NK cells
FR2655269B1 (fr) * 1989-12-01 1994-02-11 Curie Universite Pierre Marie Proteines empechant l'interaction entre un fragment fc d'une immunoglobuline et son recepteur et utilisation en therapeutique, notamment dans le traitement des affections liees aux virus hiv.
FR2702481B1 (fr) * 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique.
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
WO1995014772A1 (fr) * 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
US6444789B1 (en) * 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
FR2739560B1 (fr) * 1995-10-09 1997-11-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite du cd16 humain soluble dans le traitement de l'infection par le virus vih
US6648453B2 (en) 1997-07-15 2003-11-18 Silverbrook Research Pty Ltd Ink jet printhead chip with predetermined micro-electromechanical systems height
US7468139B2 (en) 1997-07-15 2008-12-23 Silverbrook Research Pty Ltd Method of depositing heater material over a photoresist scaffold
US7195339B2 (en) 1997-07-15 2007-03-27 Silverbrook Research Pty Ltd Ink jet nozzle assembly with a thermal bend actuator
US6935724B2 (en) 1997-07-15 2005-08-30 Silverbrook Research Pty Ltd Ink jet nozzle having actuator with anchor positioned between nozzle chamber and actuator connection point
US6855264B1 (en) 1997-07-15 2005-02-15 Kia Silverbrook Method of manufacture of an ink jet printer having a thermal actuator comprising an external coil spring
US7556356B1 (en) 1997-07-15 2009-07-07 Silverbrook Research Pty Ltd Inkjet printhead integrated circuit with ink spread prevention
US6712453B2 (en) 1997-07-15 2004-03-30 Silverbrook Research Pty Ltd. Ink jet nozzle rim
US7287836B2 (en) * 1997-07-15 2007-10-30 Sil;Verbrook Research Pty Ltd Ink jet printhead with circular cross section chamber
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US7465030B2 (en) 1997-07-15 2008-12-16 Silverbrook Research Pty Ltd Nozzle arrangement with a magnetic field generator
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DK1436427T3 (da) * 2001-10-19 2008-12-08 Chru Tours Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
EP1513554B9 (en) * 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
BRPI0406724A (pt) * 2003-01-13 2005-12-20 Macrogenics Inc Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
PL2921500T3 (pl) * 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
JP2009501913A (ja) 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
PT1919503E (pt) 2005-08-10 2015-01-05 Macrogenics Inc Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
BRPI0906309A2 (pt) 2008-04-02 2020-05-26 Macrogenics, Inc Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
RU2549695C2 (ru) 2009-12-21 2015-04-27 Ридженерон Фармасьютикалз, Инк. ГУМАНИЗИРОВАННЫЕ FCγR МЫШИ
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2492689B8 (en) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Detection of antibodies using an improved immune complex (IC) ELISA
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
PT3129400T (pt) 2014-04-08 2020-05-27 Regeneron Pharma Animais não humanos que possuem recetores fc-gamma humanizados
EP3162895B1 (en) * 2014-06-27 2020-11-25 Tosoh Corporation Improved fc-binding protein, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said adsorbent
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11202008620VA (en) 2018-03-26 2020-10-29 Regeneron Pharma Humanized rodents for testing therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199153A (en) * 1878-01-15 Improvement in sulky-plows
CA1340935C (en) * 1986-05-29 2000-03-28 Ian F.C. Mckenzie Fc gamma receptor
FR2611913B1 (fr) * 1987-02-24 1994-04-15 Khayat David Procede de dosage des recepteurs fc gamma solubles seriques, coffret de dosage correspondant et applications
WO1989008114A1 (en) * 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
JP2657221B2 (ja) * 1988-05-27 1997-09-24 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ ヒトＦｃγレセプター▲ＩＩＩ▼

Also Published As

Publication number Publication date
US6294347B1 (en) 2001-09-25
AU3740089A (en) 1989-12-12
EP0791653B9 (en) 2006-08-30
DE68929256D1 (de) 2000-11-23
DE68929546T2 (de) 2006-09-21
EP0449828A1 (en) 1991-10-09
KR0149012B1 (ko) 1998-08-17
DE68929256T2 (de) 2001-05-17
GR3034698T3 (en) 2001-01-31
ATE321134T1 (de) 2006-04-15
US5976831A (en) 1999-11-02
DE68929546T4 (de) 2007-03-08
DE68929546D1 (de) 2006-05-11
ES2150898T3 (es) 2000-12-16
WO1989011490A1 (en) 1989-11-30
EP0343950A2 (en) 1989-11-29
EP0791653B1 (en) 2006-03-22
EP0343950B1 (en) 2000-10-18
JP2657221B2 (ja) 1997-09-24
JPH03501484A (ja) 1991-04-04
HK1001403A1 (en) 1998-06-19
ES2262163T3 (es) 2006-11-16
EP0343950A3 (en) 1991-07-10
EP0791653A1 (en) 1997-08-27
ATE197053T1 (de) 2000-11-15

Similar Documents

Publication Publication Date Title
KR900701843A (ko) 사람 Fcr 수용체 III
Robbins et al. Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients
US4079127A (en) Thymosin alpha 1
Bird et al. Identification of a common class of high affinity receptors for both types of porcine interleukin-1 on connective tissue cells
Light et al. Current status of the structure of papain: the linear sequence, active sulfhydryl group, and the disulfide bridges
Eto et al. Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1
Elzinga et al. Complete amino-acid sequence of actin of rabbit skeletal muscle
Uzé et al. Domains of interaction between alpha interferon and its receptor components
Yoo et al. COOH-terminal amino acids of the alpha subunit play common and different roles in human choriogonadotropin and follitropin
Yamamoto et al. Purification and characterization of a GTP-binding protein with a molecular weight of 20,000 in bovine brain membranes. Identification as the rho gene product.
IT1153265B (it) Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi
Kuby et al. Studies on adenosine triphosphate transphosphorylases. Amino acid sequence of rabbit muscle ATP-AMP transphosphorylase
Chance Amino acid sequences of proinsulins and intermediates
Hopp et al. Amino acid sequence and variant forms of favin, a lectin from Vicia faba.
Kawamura et al. Inhibition of rhodopsin phosphorylation by non-myristoylated recombinant recoverin
Pierce et al. Antibodies to reduced S-carboxymethylated alpha subunit of bovine luteinizing hormone and their application to study of the purification of gonadotropin from salmon (Oncorhynchus tshawytscha) pituitary glands
Spitzer et al. Hagfish slime gland thread cells. II. Isolation and characterization of intermediate filament components associated with the thread.
KR880009125A (ko) 재조합 숙주에 의해 제조되는 췌장분비 트립신 억제제 및 그의 변이체, 그의 방법, 표현벡터 및 재조합 숙주 및 그의 제약상 용도
KR910016769A (ko) 펩티드 및 그의 용도
Appella et al. Partial amino acid sequence of mouse β2-microglobulin
Gitlin et al. Studies on the biotin-binding site of streptavidin. Tryptophan residues involved in the active site
Asano et al. Localization of various forms of the γ subunit of G protein in neural and nonneural tissues
ABEL et al. Structural differences in the hinge region of human gamma A myeloma proteins of different subclasses
Milstein et al. Disulphide bridges of the heavy chain of human immunoglobulin G2
Bhattacharyya et al. Thyroid tubulin, purification and properties

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120518

Year of fee payment: 15

EXPY Expiration of term